A drug for prevention and treatment of helminthiasis in animals "albanain"

 

(57) Abstract:

A drug for prevention and treatment of helminthiasis in animals is recommended for use against moniezia, dictional, gastrointestinal of strongest, trichocera, dicroceliums, Strongyloides and fasciolae. The drug contains albendazole and chalk or zeolites. The combination of components in a certain ratio, we can reduce the number of treatments of animals due to prolonged action of the drug and to increase their effectiveness at lower doses.

The invention relates to the field of veterinary medicine, namely to helminthology.

Known drugs for the prevention and treatment of helminthiasis in animals - lexical, bithionol, carbon tetrachloride, fenasal, nilverm, fascioli and other (Veterinary formula with the basics of treatment and prevention. Ed. by I. E. Mozgova. M: Agropromizdat, 1988, S. 336 - 351).

However, the known drugs do not have a wide range of actions, many of them have side effects.

Well-known medication for the treatment of helminthiasis, containing as active substance albendazole (German patent N 33/15607, A 61 K 31/415, 11.03.83).

However, the drug has a very complex composition, including doten drug for the prevention and treatment of helminthiasis in animals albendazole. (Demidov, I. C. Anthelmintic in veterinary medicine, M.: Kolos, 1982, S. 279 - 283).

The drug has low toxicity, it has a wide range of actions, but not active, therefore requires additional processing animals.

The aim of the invention is to obtain a product of prolonged action, high performance, for which it would not be necessary in the re-treatment of animals. This objective is achieved in that a preparation containing albendazole, added chalk or zeolites in the following ratio, wt. % : albendazole -10 - 50, chalk or zeolites - the rest.

Analysis of the known prior art has shown the absence of any information about technical solutions, all the same essential features with the stated drug that allows to make a conclusion on the conformity of the proposed technical solution the condition of patentability "Novelty."

Nor were decisions that have signs consistent with the distinctive features of the proposed technical solution, which allows to make a conclusion on compliance with a condition of patentability "Inventive step".

Get the drug by mixing components.

Albanain 10 - 50% has a pronounced activity against moniezia, dictional, gastrointestinal of strongest, trichocera, dicroceliums, Strongyloides and fasciolae.

The drug has low toxicity, median lethal dose for white mice in oral introduction 2600 mg/kg (4 hazard class).

Cattle, albanain 10% used individually with concentrated feed once: in acute fasciolosis 0.0075 g/kg LW, chronic fasciolosis when monitise, nematolosa dairy and gastrointestinal tract = 0.01 g/kg of LW.

Sheep, albanain 10% designate an individual and group method. Individually the drug is prescribed for monitise, dictyocaulus and gastrointestinal strongylata 0.005 g/kg LW, against adults of dicroceliums - 0.0075 g/kg of LW.

Group way - in the same doses in a mixture with feed once. The product weighed no more than 150 sheep, thoroughly mixed with the Wai free access to these animals.

Chronic fasciolosis sheep the drug is administered in a dose of 0.0075 g/kg LW. Against adult dicroceliums - dose of 0.015 g/kg of LW.

The pigs used albanain 10% once the group method with concentrated feed in the morning. The product weighed no more than 50 heads at the rate of 0.01 g/kg of LW, mixed with half the normal feed and evenly laid in a manger, allowing free access of animals.

Albanain 50% of the applied dose rate of 0.05 g/kg body weight (LW 0.005 g/kg) when monithes, dictyocaulus and gastrointestinal strongylata group method in the same doses in a mixture with feed once. The product weighed no more than 150 sheep, thoroughly mixed with the feed at the rate of 50 - 100 g of feed per animal. A therapeutic mixture evenly laid in a manger, providing free access to these animals. Chronic fasciolosis sheep the drug is administered in a dose of 0.075 g/kg of body weight, which corresponds to 0.0075 g/kg of LW.

Against adult dicroceliums 0.15 g/kg of body weight or 0,015 g/kg LW. Albanain 50% of tablets used individually in the same doses.

The pigs used albanain 50% once the group way to the end,01 g/kg), mix with half the normal feed and evenly laid in a manger, allowing free access of animals.

The use of albulena 10 - 50% reduces the number of treatments of animals due to prolonged action of the drug and to increase their effectiveness at lower doses.

In therapeutic doses, the drug has no hepatoxicity, embryotoxic properties, does not cause side effects.

A drug for prevention and treatment of helminthiasis in animals containing albendazole, characterized in that it further comprises a chalk or zeolites in the following ratio, wt.%:

Albendazole - 10 - 50

Chalk or zeolites - Ostalnoe

 

Same patents:

The invention relates to medicine

The invention relates to the creation of new chemical compounds with anticonvulsant, antihypoxic and antioxidant activity and belonging to a new class of anticonvulsants
The invention relates to pharmaceutical industry

The invention relates to medicine, namely to the way the pharmacological treatment of acute respiratory viral infections and influenza using an inducer of endogenous interferon-Dibazol

The invention relates to a method for the oral drugs with intersolubility coating, which contain unstable in the acidic environment of the connection, in particular to oral medication with intersolubility coating obtained in the form of a stable in the acidic environment of standard doses in the form of an inclusion complex obtained by the reaction of a benzimidazole derivative is unstable in an acidic compound with cyclodextrin in alkaline solution

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating patients with uterine cervix cancer with relapses in parametral fiber and in case of no possibility for radical operative interference and effect of previous radiation therapy. During the 1st d of therapy one should intravenously inject 30 mg platidiam incubated for 1 h at 37 C with 150 ml autoblood, during the next 3 d comes external irradiation per 2.6 G-r. During the 5th d of therapy one should introduce the following composition into presacral space: 60 ml 0.5%-novocaine solution, 1 ml hydrocortisone suspension, 2 ml 50%-analgin solution, 1 ml 0.01%-vitamin B12 solution, 1.6 g gentamycine, 800 mg cyclophosphan, 10 mg metothrexate. These curative impacts should be repeated at mentioned sequence four times. The method enables to decrease radiation loading and toxic manifestations of anti-tumor therapy at achieving increased percent of tumor regression.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to a group of new derivatives of 4,5-dihydro-1H-pyrazole of the general formula (I):

wherein R means phenyl, thienyl or pyridyl and these indicated groups can be substituted with (C1-C3)-alkoxy-group or halogen atom; R1 means phenyl that can be substituted with (C1-C3)-alkoxy-group or pyridyl group; R2 means hydrogen atom or hydroxy-group; Aa means one group among the following groups: (i) , (ii) , (iii) , (iv) or (v) ; R4 and R5 mean independently from one another hydrogen atom or (C1-C8)-branched or unbranched alkyl; or R4 means acetamido- or dimethylamino-group or 2,2,2-trifluoroethyl, or phenyl, or pyridyl under condition that R5 means hydrogen atom; R6 means hydrogen atom at (C1-C3)-unbranched alkyl; Bb means sulfonyl or carbonyl; R3 means benzyl, phenyl or pyridyl that can be substituted with 1, 2 or 3 substitutes Y that can be similar or different and taken among the group including (C1-C3)-alkyl or (C1-C3)-alkoxy-group, halogen atom, trifluoromethyl; or R3 means naphthyl, and its racemates, mixtures of diastereomers and individual stereoisomers and as well as E-isomers, Z-isomers and mixture of E/Z-compounds of the formula (I) wherein A has values (i) or (ii), and its salt. These compounds are power antagonists of Cannbis-1 (CB1) receptor and can be used for treatment of psychiatric and neurological diseases. Except for, invention relates to a pharmaceutical composition used for treatment of some diseases mediated by CB1-receptor, to a method for preparing this composition, a method for preparing representatives of compounds of the formula (I) wherein Aa means group of the formulae (i) or (ii), intermediate compounds used for preparing compounds of the formula (I) and to a method for treatment of some diseases mediated by CB1-receptor.

EFFECT: valuable medicinal properties of compounds.

16 cl, 9 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new 1-(p-thienylbenzyl)-imidazoles of the formula (I): , wherein indicated residues represent the following values: R(1) means halogen atom, (C1-C4)-alkoxyl, (C1-C8)-alkoxyl wherein one carbon atom can be replaced with heteroatom oxygen atom (O); R(2) means CHO; R(3) means aryl; R(4) means hydrogen halogen atom; X means oxygen atom; Y means oxygen atom or -NH-; R(5) means (C1-C6)-alkyl; R(6) means (C1-C5)-alkyl in their any stereoisomeric forms and their mixtures taken in any ratios, and their physiologically acceptable salts. Compounds are strong agonists of angiotensin-(1-7) receptors and therefore they can be used as a drug for treatment and prophylaxis of arterial hypertension, heart hypertrophy, cardiac insufficiency, coronary diseases such as stenocardia, heart infarction, vascular restenosis after angioplasty, cardiomyopathy, endothelial dysfunction or endothelial injures, for example, as result of atherosclerosis processes, or in diabetes mellitus, and arterial and venous thrombosis also. Invention describes a pharmaceutical composition based on above said compounds and a method for their applying also.

EFFECT: valuable medicinal properties of compounds and composition.

10 cl, 19 ex

FIELD: organic chemistry and pharmaceutical compositions.

SUBSTANCE: invention relates to new 3-(5)-heteroaryl-substituted pyrazoles of formula I , tautomers or pharmaceutically acceptable salt of compounds and tautomers. In formula R1 is hydride, piperidinyl substituted with methyl, lower alkyl optionally substituted with halogen, hydroxyl, lower alkylanimo or morpholino; R2 is hydride, lower alkyl, amino, aminocarbonylamino, lower alkylaminocarbonylamino, lower alkylsulfonylamino, aminosulfonylamino, lower alkylaminosulfonylamino; Ar1 is phenyl optionally substituted with one or more independently selected halogen; HetAr2 is pyridinyl with the proviso that R2 is not amino or n-propyl when HetAr2 is pyridinyl; and HetAr2 is not 2-pyriridinyl when R2 is hydrogen or lower alkyl. Compounds of formula I have kinase p38 inhibitor activity and are useful in pharmaceutical compositions for treatment of various diseases.

EFFECT: new effective kinase p38 inhibitors.

23 cl, 6 dwg, 1 tbl, 1 ex

FIELD: veterinary science.

SUBSTANCE: a dog should be introduced with 4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazole-1-il]benzene sulfonamide or its pharmaceutically acceptable salt at daily dosage ranged about 0.1-10 mg/kg body weight.

EFFECT: higher efficiency of therapy.

4 cl,262 ex, 12 tbl

FIELD: medicine, gynecology, anesthesiology.

SUBSTANCE: invention concerns to a method for carrying out the anesthesiology assistance for woman in childbirth with accompanying bronchial asthma. Method involves administration of atropine, dimedrol, analgin and clophelin. Method involves additional intravenous administration of transamine for 5-7 min. Transamine is administrated in doses 12-14 and 15-17 mg/kg in woman in childbirth with body mass 75 kg and above and 74 kg and less, respectively. Method provides enhancing quality and safety of anesthesia in this class of woman in childbirth.

EFFECT: improved assistance method.

7 tbl, 4 ex

FIELD: medicine, dermatology, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to an antifungal gel pharmaceutical composition based on ketoconazole and clotrimazole that are derivatives of imidazole. The composition comprises ketoconazole or clotrimazole as an active component, polyethylene glycol-400 (PEG-400) as a solvent, carboxyvinyl polymer as a gel-forming agent, polyethylene glycol as a gel stabilizing agent, organic amine or inorganic bas as a regulator of pH and water taken in the definite ratio of components. The composition is prepared by dissolving active component in PEG-400, dispersing carboxyvinyl polymer in water, successive addition to dispersion propylene glycol as a stabilizing agent and regulator of pH and combination of prepared solution and gel followed by stirring the mixture up to preparing the gel composition with pH 5-7. Invention provides preparing antifungal composition with reduced adverse effect.

EFFECT: improved preparing method, valuable medicinal properties of composition.

2 cl, 1 tbl, 11 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with applying selector as a selenium-containing organic preparation to be introduced for cows and calves monthly intramuscularly at the dosage of 10 mcg/kg body weight. The method provides decreased fodder expenses for the synthesis of the production obtained.

EFFECT: higher productivity in cattle.

2 ex, 7 tbl

FIELD: organic chemistry, medicine, allergology, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to a method for treatment of patient suffering with allergic disease. Method involves administration to patient the therapeutically effective dose of pharmaceutical composition comprising compound of the formula (I)

. The compound elicits high effectiveness in treatment of allergy and shows low toxicity also.

EFFECT: improved method for treatment.

9 cl, 2 tbl, 2 dwg, 40 ex

FIELD: veterinary science.

SUBSTANCE: one should apply a selenium-containing preparation named selecor: it should be introduced on the 80-90th d of swine gestation twice at 10-15-d-long interval parenterally at the dosage of 20 mg/kg animal body weight. Application of low-toxic antioxidant as selecor enables to improve functional properties of cell membranes of placental system and endometrium and increase inspecific immune resistance in sows. It, also, enables to increase fertility in sows, values of uncomplicated deliveries and puerperal period.

EFFECT: higher viability of off-spring.

2 ex, 3 tbl

Up!